PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1375956-7 1992 In vivo activated effectors when incubated with anti-asialo-GM1 antibody plus complement lost completely their ability to lyse YAC-1 targets. G(M1) Ganglioside 60-63 ADP-ribosyltransferase 1 Mus musculus 127-132 3899934-5 1985 Moreover, the anti-YAC-1 lytic activity was partially sensitive to anti-Thy1.2 serum and was completely abrogated by treatment of peritoneal nonadherent cells with monoclonal anti-asialo GM1 antibodies. G(M1) Ganglioside 187-190 ADP-ribosyltransferase 1 Mus musculus 19-24 3206532-6 1988 Antibody and complement depletion experiments showed that both anti-YAC-1 and anti-P815 activity could be depleted with antiserum to the asialo-GM1 cell surface marker, but was unaffected by anti-Lyt-1.2 and anti-Lyt-2.2 treatment. G(M1) Ganglioside 144-147 ADP-ribosyltransferase 1 Mus musculus 68-73 7240748-3 1981 Intravenous injection of anti-asialo GM1, which has been shown to eliminate natural killer (NK) activity in vitro in the presence of complement, completely abolished NK activity against lymphoma cell line (YAC-1) in spleen cells from athymic nude mice as well as from conventional mice. G(M1) Ganglioside 37-40 ADP-ribosyltransferase 1 Mus musculus 206-211 9826367-7 1998 The cells were confirmed to be NK cells by abrogation of YAC-1 cell cytotoxicity by treatment in vitro and in vivo with anti-asialo-GM1. G(M1) Ganglioside 132-135 ADP-ribosyltransferase 1 Mus musculus 57-62